Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06029296
EARLY_PHASE1

Diclofenac as a KMO Inhibitor

Sponsor: University of Maryland, Baltimore

View on ClinicalTrials.gov

Summary

This mechanistic, proof of concept laboratory study will test the pharmacological properties of diclofenac in individuals with AUD. Participants will complete two sessions in which they will receive a single dose of diclofenac (100 mg) or matched placebo in a randomized and double blind fashion. The primary aim is to assess whether this dose of diclofenac, vs. placebo, increases circulating levels of kynurenic acid. This finding would provide evidence that diclofenac (100 mg) inhibits the kynurenine 3-monooxygenase enzyme.

Official title: Proof of Concept: Diclofenac as a KMO Inhibitor in Individuals With Alcohol Use Disorder

Key Details

Gender

All

Age Range

21 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2024-07-31

Completion Date

2026-08

Last Updated

2026-03-27

Healthy Volunteers

No

Interventions

DRUG

Diclofenac

100 mg

DRUG

Placebo

Sugar pill

Locations (1)

Maryland Psychiatric Research Center (MPRC) Treatment Research Program (TRP)

Catonsville, Maryland, United States